Celltrion to Supply Bio-Similar Worth 160 Billion KRW to Celltrion Healthcare
[Asia Economy Reporter Ji Yeon-jin] Celltrion announced on the 24th that it has signed a supply contract worth 160 billion KRW for biosimilar antibody drugs (Remsima IV, Herzuma, CT-P16) with Celltrion Healthcare. The contract period is from today until the 30th of next month.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
